Amy Emerson is the Chief Executive Officer at the MAPS Public Benefit Corporation (MAPS PBC), a fully owned subsidiary of the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS).
Working for almost two decades to make MDMA a legal, FDA-approved medicine, Amy began as a pro bono consultant for MAPS in 2003, helping to create MAPS’ clinical department and managing the MDMA Clinical Development Program.
Her painstaking time and efforts have played a key role in seeing MDMA-assisted psychotherapy as a treatment for post-traumatic stress disorder (PTSD) through clinical trials, driving it ever-closer to being a legal, accessible therapeutic treatment in the US and abroad.
Read moreMAPS Founder and Executive Director Rick Doblin, Ph.D., sits down with Aubrey Marcus to explain MAPS' multiple research, policy, and education priorities in the context of our larger, long-term goal of mass mental health.
"I hope in the big picture, by 2050, we'll have enough people with an understanding of how to use psychedelics for personal, emotional, and spiritual growth that we'll have a more spiritualized humanity to turn us more towards saving the planet from mass weapons, climate change, and prejudice," explains Doblin.
Read moreGreat news! The first Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD) replicated and expanded on Phase 2 results indicating MDMA-assisted therapy may be an effective and cost-saving treatment for PTSD resulting from any cause.
Read moreThe California chemist Sasha Shulgin is known as the ‘Godfather of MDMA,’ but his legacy lies in countless drugs that remain a mystery to scientists and psychonauts alike. Keep reading to learn more.
Read moreAs a first responder, Nick Watchorn had seen many terrible things in the course of his career. But the massive shooting of April 28, 1986 in Tanzania, Australia, completely shook his handle on reality. Now Nick is part of the experimental studies on therapeutic MDMA or PTSD treatment.
Read moreMore research with promising results on how pharmaceutical-grade MDMA can be used in combination with psychotherapy, to help patients who have a severe form of PTSD that has not responded to other treatments.
Read moreThe first safety study of using MDMA-assisted psychotherapy for patients with alcohol use disorder has been completed, with promising results.
Read moreA military psychologist is interviewed on his personal experiences with MDMA therapy and PTSD. A must read!
Read more